Where does RGNT stock trade?

Regentis Biomaterials Ltd. (RGNT) is listed on AMEX.

What sector and industry is RGNT in?

Regentis Biomaterials Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.

When did Regentis Biomaterials Ltd. go public?

Regentis Biomaterials Ltd. (RGNT) completed its IPO in 2025.

What companies are similar to RGNT?

Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RGNT side-by-side with any of them on Quantisnow.

How can I track RGNT on Quantisnow?

Quantisnow aggregates Regentis Biomaterials Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RGNT to receive live email and push alerts on every new disclosure.

RGNT

AMEX

Regentis Biomaterials Ltd.

SectorHealth CareIndustryBiotechnology: Pharmaceutical PreparationsIPO2025

$1.99+0.05 (+2.58%)

News25/Ratings0

Price$1.99+0.02 (+1.02%)

01:45 PM07:45 PM

News · 26 weeks50+67%

2026-01-252026-07-19

Mix2790d

SEC Filings16(59%)
Insider6(22%)
Market4(15%)
Other1(4%)

Latest news

25 items

5dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
5dNEWS
Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
Patent expands intellectual property protection in one of the world's largest cartilage repair marketsGelrinC is a cell-free hydrogel delivered in a single ~10-minute procedure eliminating the need for cell harvesting, lab processing, and surgeries-potentially setting a new standard of care for knee cartilage repair HERZLIYA, IL / ACCESS Newswire / July 20, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced today that the Japan Patent Office has issued a Notice of Allowance for the Company's patent application titled "Organic Solvent Free Compositions Comprising Protein-Polymer
10dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
10dNEWS
Regentis Receives European Regulatory Approval for New GelrinC Manufacturing Process, Increasing Production Yield by 400% Ahead of European Commercial Launch
European Notified Body approves next-generation manufacturing process that increases production 5-fold, lowers manufacturing costs, improves safety and enables scalable commercial productionGelrinC®, which is approved for sale in the European Union, is pioneering knee cartilage repair with an off-the-shelf cell-free hydrogel implant HERZLIYA, IL / ACCESS Newswire / July 15, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, announced today it has received approval from the European Notified Body to manufacture GelrinC® using its next-generation solvent-free manufacturing process.The appro
11dSEC
SEC Form EFFECT filed by Regentis Biomaterials Ltd.
EFFECT - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
11dINSIDER
SEC Form 4 filed by Director Alpert Susan Phd Md
4 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
11dSEC
SEC Form 424B3 filed by Regentis Biomaterials Ltd.
424B3 - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
11dINSIDER
SEC Form 4 filed by Director Ben-Elazar Pini
4 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
11dINSIDER
SEC Form 4 filed by Director Valentine Keith
4 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
11dINSIDER
SEC Form 4 filed by Director Dykan Jeff
4 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
11dINSIDER
SEC Form 4 filed by Chief Executive Officer Geller Ehud
4 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
11dINSIDER
SEC Form 4 filed by Director Cohen-Arazi Efraim
4 - REGENTIS BIOMATERIALS LTD. (0001912966) (Issuer)
15dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
16dSEC
SEC Form F-1 filed by Regentis Biomaterials Ltd.
F-1 - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
22dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
29dSEC
SEC Form D filed by Regentis Biomaterials Ltd.
D - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
36dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
37dNEWS
Regentis Biomaterials Announces Pricing of a $6.5 Million Private Placement
HERZLIYA, IL / ACCESS Newswire / June 17, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair solutions, today announced that it has entered into definitive securities purchase agreements with accredited and institutional investors for the issuance and sale of ordinary shares (or pre-funded warrants in lieu thereof) together with warrants , at a purchase price of $3.50 per ordinary share and accompanying ordinary warrant (or $3.4999 per pre-funded warrant and accompanying ordinary warrant), in a private placement, for expected aggregate gross proceeds of approximately $6.5 million, before deducting p
40dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
40dSEC
SEC Form RW filed by Regentis Biomaterials Ltd.
RW - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
46dSEC
Amendment: SEC Form F-1/A filed by Regentis Biomaterials Ltd.
F-1/A - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
47dSEC
SEC Form 6-K filed by Regentis Biomaterials Ltd.
6-K - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
47dNEWS
Regentis to Commence European Surgeon Training for GelrinC in Knee Cartilage Repair as Commercial Launch Preparations Accelerate
GelrinC®, positioned as the first off-the-shelf cell-free hydrogel implant for knee cartilage repair, is approved for sale in the European UnionRegentis is growing its network of European Centers of Excellence designed to support surgeon education, clinical guidance, and knowledge sharing around cartilage repair and the use of GelrinCGelrinC's 10-minute procedure offers a safe and effective alternative to traditional microfracture and complex cell-based therapies addressing a $3 billion U.S. market HERZLIYA, ISRAEL / ACCESS Newswire / June 8, 2026 / Regentis Biomaterials Ltd. ("Regentis" or the "Company") (NYSE:RGNT), a regenerative medicine company focused on innovative tissue repair soluti
50dSEC
Amendment: SEC Form 6-K/A filed by Regentis Biomaterials Ltd.
6-K/A - REGENTIS BIOMATERIALS LTD. (0001912966) (Filer)
56dSEC
SEC Form FWP filed by Regentis Biomaterials Ltd.
FWP - REGENTIS BIOMATERIALS LTD. (0001912966) (Subject)

RGNT FAQ

5 questions

Where does RGNT stock trade?
Regentis Biomaterials Ltd. (RGNT) is listed on AMEX.
What sector and industry is RGNT in?
Regentis Biomaterials Ltd. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.
When did Regentis Biomaterials Ltd. go public?
Regentis Biomaterials Ltd. (RGNT) completed its IPO in 2025.
What companies are similar to RGNT?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare RGNT side-by-side with any of them on Quantisnow.
How can I track RGNT on Quantisnow?
Quantisnow aggregates Regentis Biomaterials Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow RGNT to receive live email and push alerts on every new disclosure.